K

Active Director Director DIN 03564043
DIN 03564043 First appointment Jun 2011 Primary industry Chemicals and Materials
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2011
Shareholding value •••• Premium profile

About Keerthi

Data last updated:

Keerthi is a Director at Cornel Pharmaceuticals Private Limited (since 2011). The company operates in Chemicals and Materials. Cornel Pharmaceuticals Private Limited reported revenue of ₹18.56 Cr (FY 2025).

DIN 03564043
Primary Designation Director
Industry Chemicals and Materials
First Appointment 30 Jun 2011
Oldest Company Age 42 yrs
Largest company Cornel Pharmaceuticals Private Limited · ₹18.56 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Jun 20111984₹18.56 Cr (FY 2025)Active

Board colleagues of Keerthi

Directorship timeline

Open interactive timeline →
Cornel Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Keerthi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Keerthi

Keerthi currently holds 1 directorship: Cornel Pharmaceuticals Private Limited (Director, since 30 Jun 2011, revenue ₹18.56 Cr (FY 2025)).

Keerthi was first appointed on 30 Jun 2011 as Director at Cornel Pharmaceuticals Private Limited.

The current boards of Keerthi's companies include Sharmila Rajkumar Parekh (Cornel Pharmaceuticals Private Limited), Vaibhav Rajkumar Parekh (Cornel Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available